BCAX
Bicara Therapeutics Inc.
Next earnings Aug 10, 2026 · consensus $-0.85 EPS
Last earnings +1.5% on 2026-05-11
$26.87
▲ +2.01%$26.87▲ +188.30%
over 1Y
L $8.71EODHDH $26.87
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.0%
1W+9.5%
1M+24.5%
3M+46.3%
YTD+64.0%
1Y+188.3%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 21 analysts
Buy
Conservative balance sheet (liabilities/equity 0.07x).
Bicara Therapeutics Inc. shows limited reported revenue, and -34.4% ROE.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$39.9M | -$82.4M | -$156M |
| Net income | -$52.0M | -$68.0M | -$138M |
| Diluted EPS | -$89.61 | -$4.05 | -$2.52 |
| Net margin | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.66B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-7.8%
FCF yield-6.1%
Quality & risk
ROIC (est.)-30.6%
Free cash flow-$107M
Total debt—
Net cash$96.7M
Piotroski F-Score1/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+20.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗144Filing2026-06-25open ↗4Period ending 2026-06-092026-06-10open ↗4Period ending 2026-06-092026-06-10open ↗4Period ending 2026-06-092026-06-10open ↗4Period ending 2026-06-092026-06-10open ↗4Period ending 2026-06-092026-06-10open ↗4Period ending 2026-06-092026-06-10open ↗4Period ending 2026-06-092026-06-10open ↗8-KPeriod ending 2026-06-092026-06-10open ↗144Filing2026-06-01open ↗4Period ending 2026-05-212026-05-26open ↗144Filing2026-05-26open ↗
Frequently asked
- Is Bicara Therapeutics Inc. (BCAX) a buy?
- BCAX currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.07x).
- What is Bicara Therapeutics Inc.'s quality score?
- BCAX scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0002023658, latest 10-Q filed 2026-05-11) · EODHD · as of 6/22/2026, 11:31:57 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.